0001209191-21-043377.txt : 20210625 0001209191-21-043377.hdr.sgml : 20210625 20210625180830 ACCESSION NUMBER: 0001209191-21-043377 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210623 FILED AS OF DATE: 20210625 DATE AS OF CHANGE: 20210625 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GOODMAN JESSE CENTRAL INDEX KEY: 0001756929 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37766 FILM NUMBER: 211049410 MAIL ADDRESS: STREET 1: C/O INTELLIA THERAPEUTICS, INC. STREET 2: 40 ERIE STREET, SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Intellia Therapeutics, Inc. CENTRAL INDEX KEY: 0001652130 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 364785571 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 40 ERIE STREET STREET 2: SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-285-6200 MAIL ADDRESS: STREET 1: 40 ERIE STREET STREET 2: SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-06-23 0 0001652130 Intellia Therapeutics, Inc. NTLA 0001756929 GOODMAN JESSE C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET; SUITE 130 CAMBRIDGE MA 02139 1 0 0 0 Common Stock 2021-06-23 4 A 0 2094 0.00 A 2094 D Stock Option (right to buy) 83.59 2021-06-23 4 A 0 3382 0.00 A 2031-06-22 Common Stock 3382 3382 D Stock Option (right to buy) 18.52 2028-10-28 Common Stock 38000 38000 D Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. This option was granted on June 23, 2021 with respect to 3,382 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. As was previously reported, this option was granted on October 29, 2018 with respect to 38,000 shares of Common Stock, with 33% vesting on October 29, 2019 and the remaining 67% vesting in eight substantially equal quarterly installments thereafter. The expiration date of the reported grant was mistakenly reported in a Form 4 filed on 10/31/2018 as 10/28/2018. /s/Jose E. Rivera, Attorney-In-Fact 2021-06-25